Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions

European Respiratory Journal

Volumn 24, Issue 2, 2004, Pages 263-266

  Kishi, K ^a   Homma, S ^a   Sakamoto, S ^a   Kawabata, M ^a   Tsuboi, E ^a   Nakata, K ^b   Yoshimura, K ^a  

^a TORANOMON HOSPITAL   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Doxorubicin; Lung cancer; Malignant pleural effusion; OK 432; Pleurodesis

Indexed keywords

ALANINE AMINOTRANSFERASE; DOXORUBICIN; NONSTEROID ANTIINFLAMMATORY AGENT; PICIBANIL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FEVER; HUMAN; LIVER DYSFUNCTION; LUNG CANCER; MALE; PLEURA EFFUSION; PLEURODESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PYOGENES; THORAX DRAINAGE; THORAX PAIN; TUBE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRALESIONAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PICIBANIL; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RISK ASSESSMENT; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 4344714103     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.00137403     Document Type: Article

References (23)

1. Kvale PA, Simoff M, Prakash UBS. Palliative care. Chest 2003; 123: 284S-311S.
2. American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000; 162: 1987-2001.
3. Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 1994; 120: 56-64.
4. Okamoto H, Shoin S, Koshimura S, Shimizu R. Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol 1967; 11: 323-336.
5. Reshad K, Inui K, Takeuchi Y, Takahashi Y, Hitomi S. Treatment of malignant pleural effusion. Chest 1985; 88: 393-397.
6. Luh K-T, Yang P-C, Kuo S-H, Chang D-B, Yu C-J, Lee L-N. Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial. Cancer 1992; 69: 674-679.
7. Nio Y, Nagami H, Tamura K, et al. Multi-institutional randomized clinical study on the comparative effects of intracavital chemothrapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion. Br J Cancer 1999; 80: 775-785.
8. Urata A, Nishimura M, Ota K. Randomized controlled study of OK-432 in the treatment of cancerous pleurisy. Gan To Kagaku Ryoho 1983; 10: 1467-1503.
9. Kishi K, Kawabata M, Tsuboi E, et al. Pleurodesis with a combination of OK-432 and adriamycin for malignant pleural effusions caused by lung cancer. Haigan 1999; 39: 261-266.
10. Sakurai Y, Tsukagoshi S, Sato H, Akiba T, Suzuki S. Tumor-inhibitory effect of a streptococcal preparation (NSC-B116209). Cancer Chemother Rep 1972; 56: 9-17.
11. National Cancer institute. NCIC-CTC grading system. http://ctep.cancer.gov/forms/CTCv204-30-992.pdf. Date updated: 30th April 1999; Date accessed: 1st April, 2000.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
13. Kimura I, Ohnishi T, Yasuhara S, Sugiyama M, Urabe Y. Immunochemotherapy in human lung cancer using the streptococcal agent OK-432. Cancer 1976; 37: 2201-2203.
14. Tokai Cooperative Study Group for Adjuvant Chemo-Immunotherapy of Stomach Cancer. A controlled study of maintenance chemoimmunotherapy vs immunotherapy alone immediately following palliative gastrectomy and induction chemoimmunotherapy for advanced gastric cancer. Cancer Chemother Pharmacol 1981; 7: 5-10.
15. Watanabe Y, Iwa T. Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer. J Bio Res Mod 1987; 6: 169-180.
16. Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimazu H, Tomita M. Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer. Br J Cancer 1992; 65: 413-416.
17. Torisu M, Katano M, Kimura Y, Itoh H, Takesue M. New approach to management of malignant ascites with a streptococcal preparation OK-432: I. Improvement of host immunity and prolongation of survival. Surgery 1983; 93: 357-364.
18. Katano M, Torisu M. New approach to management of malignant ascites with a streptococcal preparation OK-432: II. Intraperitoneal inflammatory cell-mediated tumor cell destruction. Surgery 1983; 93: 365-373.
19. Ishihara K, Hasegawa T, Okazaki M, et al. OK432 chemical pleurodesis as a standard therapy of spontaneous pneumothorax. Nihon Kyobu Shikkan Gakkai Zasshi 1988; 26: 10-15.
20. Nio Y, Zighelboim J, Berek JS, Bonavida B. Cytotoxic and cytostatic effects of the streptococcal preparation OK-432 and its subcellular fractions on human ovarian tumor cells. Cancer 1989; 64: 434-441.
21. Katano M, Torisu M. Neutrophil-mediated tumor cell destruction in cancer ascites. Cancer 1982; 50: 60-68.
22. Fujimura T, Torisu M. Neutrophil-mediated tumor cell destruction in cancer ascites: II. OK-432 attacks killer neutrophils through activation of component C5. Clin Immunopathol 1987; 43: 174-184.
23. Tanaka A, Sato T. Adhesion therapy for malignant pleural effusion (Intrapleural administration of OK-432 with minocycline). Nihon Kokyuki Gakkai Zasshi 1999; 37: 531-537.